Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro

Reference

• Abelö A, Andersson TB, Antonsson M, Naudot AK, Skinberg I, Weidolf L. 2000. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metabolism and Disposition 28:966–972.
   PubMed Web of Science ®Google Scholar
• Andersson T. 1996. Pharmacokinetics metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole, and pantoprazole. Clinical Pharmacokinetics 31:9–28.
   PubMed Web of Science ®Google Scholar
• Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. 1990. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics 47:79–85.
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. 2001a. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics 40:411–426.
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. 200 lb. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics 40:523–537.
   Google Scholar
• Andersson T, Lundborg P, Reg5rdh C-G. 1991. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. European Journal of Clinical Pharmacology 40:61–65.
   PubMed Web of Science ®Google Scholar
• Barradell LB, Faulds D, McTavish D. 1992. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 44:225–250.
   PubMed Web of Science ®Google Scholar
• Bossche HV, Willemsens G, Roels I, Bellens D, Moereels H, Coene M-C, Le Jeune L, Lauwers W, Janssen PAJ. 1990. R76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. Biochemical Pharmacology 40:1707–1718.
   PubMedGoogle Scholar
• Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248–254.
   PubMed Web of Science ®Google Scholar
• Carabaza A, Cabré F, Garcia AM, Rotllan E, Garcia ML, Mauleón D. 1997. Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofen. Chirality 9:281–285.
   PubMed Web of Science ®Google Scholar
• Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J. 2004. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates. Chirality 16:79–85.
   PubMed Web of Science ®Google Scholar
• Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, Sano H. 2001. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine, and omeprazole. Xenobiotica 31:1–10.
   PubMed Web of Science ®Google Scholar
• Gustayson LE, Kaiser JF, Edmonds AL, Locke CS, Debartolo ML, Schneck DW. 1995. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrobial Agents and Chemotherapy 39:2078–2083.
   PubMedGoogle Scholar
• Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S. 1987. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. European Journal of Clinical Pharmacology 33:369–373.
   PubMedGoogle Scholar
• Hutzler JM, Kolwankar D, Hummel MA, Tracy TS. 2002. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metabolism and Disposition 30:1194–1200.
   PubMed Web of Science ®Google Scholar
• Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. 1996. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. European Journal of Clinical Pharmacology 57:709–715.
   Google Scholar
• Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. 2003. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metabolism and Disposition 31:1227–1234.
   PubMed Web of Science ®Google Scholar
• Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG. 2002. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clinical Pharmacology and Therapeutics 72:90–99.
   PubMed Web of Science ®Google Scholar
• Ko JW, Soukhova N, Thacker D, Chen P, Flocldiart DA. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition 25:853–862.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. 1989. The specificity of inhibition of debrisoquin 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochemical Pharmacology 38:2795–2799.
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Krishnarnachary N, Shou M, Ogai A, Rarise RA, Rettie AE, Gonzalez FJ, Tracy TS. 1998. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137–4147.
   PubMed Web of Science ®Google Scholar
• Labenz J, Petersen KU, Rösch W, Koelz HR. 2003. A summary of food and drug administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Alimentary Pharmacology and Therapeutics 17:1015–1019.
   PubMed Web of Science ®Google Scholar
• Lamb DC, Baldwin BC, Kwon-Chung KJ, Kelly SL. 1997. Stereoselective interaction of the azole antifungal agent 5CH39304 with the cytochrome P-450 monooxygenase system isolated from Ctyptococcus neoformans. Antimicrobial Agents and Chemotherapy 41:1465–1467.
   Google Scholar
• Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Ganse EV. 1992. Influence of lansoprazole treatment on diazepam plasma concentrations. Clinical Pharmacology and Therapeutics 52:458–463.
   PubMedGoogle Scholar
• Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR, Cha IJ, Shin JG. 2004. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica 34:429–438.
   PubMed Web of Science ®Google Scholar
• McCarthy DM, McLaughlin T, Yazdani C, El Serag HB, Griffis DL. 2002. Effects of co-therapy with early proton pump inhibitors (PPIs) on the occurrence of side effects of other drugs with potential for interaction with PPIs: a cohort study. Gastroenterology 122:A210.
   Google Scholar
• Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. 1999. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (GYP) enzymes: assessment of human GYP inhibition potential. Xenobiotica 29:53–75.
   PubMed Web of Science ®Google Scholar
• Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Longman MJ, Williams J, Richens A. 1987. Oral phenytoin pharmacokinetics during omeprazole therapy. British Journal of Clinical Pharmacology 24:543-545. Segel IH. 1975. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: Wiley.
   Google Scholar
• Shin JG, Kane K, Flockhart DA. 2001. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. British Journal of Clinical Pharmacology 51:45–52.
   PubMed Web of Science ®Google Scholar
• Shin JG, Soukhova N, Flockhart DA. 1999. Effect of antipsychotic drugs on human liver cytochrome P450 (GYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metabolism and Disposition 27:1078–1084.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kneller MB, Haining RL,, Trager WF, Rettie AE. 2002. (±)-N-3-Benzylnirvanol and (—)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 30:235–239.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Ishizaki T. 2001, Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of 5-mephenytoin. Clinical Pharmacology and Therapeutics 69:108–113.
   PubMedGoogle Scholar
• Tybring G, Bottiger Y, Widen J, Bertilson L. 1997. Enantioselective hydroxylation of omeprazole catalysed by CYP2C19 in Swedish white subjects. Clinical Pharmacology and Therapeutics 62:129–137.
   PubMed Web of Science ®Google Scholar
• Unge P, Svedberg LE, Nordgren A, Blom H, Andersson T, Lagerstrom PO, Idström JP. 1992. A study of the interaction of omeprazole and warfarin in anticoagulated patients. British Journal of Clinical Pharmacology 34:509–512.
   PubMed Web of Science ®Google Scholar